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Abstract: 
Aims: To assess stroke rate after transcatheter mitral valve repair (TMVR) with MitraClip, 
comparing it with surgical mitral valve repair (SMVR) and optimal medical treatment (OMT). 
 
Methods and Results: We systematically searched PubMed, Embase and Cochrane Controlled 
Register of Trials, in December 2018, for studies comparing TMVR with SMVR and/or OMT for 
the treatment of severe mitral regurgitation. Random-effects and cumulative meta-analysis was 
performed. Ten studies were included: seven of TMVR versus SMVR and three of TMVR versus 
OMT, providing a total of 1881 patients and 61 pooled strokes (16 in TMVR versus SMVR and 45 
in TMVR versus OMT). There was no difference in stroke incidence between TMVR and SMVR 
(pooled OR 0.49 [0.17, 1.42], P=0.19). Cumulative meta-analysis showed a significantly lower 
stroke rate in TMVR, compared to SMVR (OR 0.4 [0.24, 0.67], P< 0.01). For TMVR versus OMT, 
no difference in stroke rate was identified (pooled OR 1.09 [0.60, 1.97], P=0.79). Post-procedure 
de novo atrial fibrillation was more frequent in SMVR when compared with TMVR. 
 
Conclusions:  
Although with a low number of pooled events, there was a trend for a lower post-procedure 
stroke in TMVR when compared with SMVR and a similar one between TMVR and OMT alone. 
 
 
Classifications: mitral valve repair, stroke, atrial fibrillation, anticoagulant therapy 
 
Condensed abstract:  A systematic review assessed stroke rate after transcatheter mitral valve 
repair (TMVR) with MitraClip, comparing it with surgical mitral valve repair (SMVR) and optimal 
medical treatment (OMT). Ten studies were included providing a total of 1881 patients. Post-
procedure TMVR stroke rate was similar to that of patients managed with OMT only. For the 
same outcome, results favoured TMVR compared with SMVR. A lower incidence of post-
procedure de novo atrial fibrillation was recorded for TMVR compared to SMVR patients. 
 
Abbreviations: 
TMVR transcatheter mitral valve repair  
SMVR surgical mitral valve repair  
OMT optimal medical treatment 
MR mitral regurgitation 
AF atrial fibrillation 
RCTs Randomised Controlled Trials 
CI confidence intervals 
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Introduction: 
It is well-established that surgical mitral valve repair (SMVR) is the summum treatment for 
severe mitral regurgitation (MR). However, a large proportion of patients are deemed 
unsuitable for surgical treatment, thus representing a striking unmet need in cardiovascular 
medicine1. So far, in patients with both primary and secondary symptomatic MR who are judged 
inoperable, only the edge-to-edge repair technique with MitraClip (Abbott Vascular Inc, Santa 
Clara, CA, USA) is globally used (class IIb indication in the most recent European Society of 
Cardiology Guidelines)2. 
The MitraClip is inspired by the surgical Alfieri technique, which creates a double orifice mitral 
area3. As a result, physiology of diastolic transmitral flow is modified, leading to some restriction 
in left ventricle filling. Thus, this hemodynamic profile could result in blood stasis, an increased 
risk of left atrial thrombosis and, consequently, the risk of thromboembolic events4-7. 
Additionally, atrial fibrillation (AF) complicates the course of MR and is itself a risk factor for 
stroke and peripheral embolic events8. Although this rationale might seem insufficient to offset 
cardiac surgery stroke risk, it may embody the recommendation for anticoagulation, particularly 
with vitamin K antagonists, which are the only oral anticoagulants indicated in both mitral 
prosthesis and mitral stenosis9. Despite this, no strict peri and post-MitraClip procedure 
antithrombotic therapies have been defined so far and distinct protocols are currently being 
applied10, 11. 
Systematic reviews support the long-term safety of transcatheter mitral valve repair (TMVR) 
with the MitraClip for degenerative and functional MR plus the durability of MR reduction12, 13. 
Recent meta-analysis demonstrated that, compared with conservative treatment alone, TMVR 
is associated with significant relative risk reduction of death from any cause and heart failure in 
high-risk patients with left ventricular disfunction14, 15. However, none of these reviews 
specifically analysed stroke incidence. In 2018, the COAPT trial16 reinforced the increased safety 
of the edge-to-edge repair technique compared to optimal medical treatment (OMT) while the 
MITRA-FR trial17 reported no significant difference in adverse effects between the two groups.  
We aim to systematically review the published literature on the comparison between the TMVR 
with the MitraClip device and both SMVR and OMT groups of patients, analysing stroke 
incidence among these therapeutic options for MR. 
 
Methods 
Protocol and registration 
This study was designed according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement. A registration (CRD42018117614) in the PROSPERO 
database was made at inception. 
 
Literature search  
Based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis we 
systematically searched PubMed, Embase, and Cochrane Controlled Register of Trials (CENTRAL) 
on 5th December 2018, for both interventional and observational studies comparing TMVR with 
SMVR and/or OMT for the treatment of severe MR. The search was limited by language (English, 
French, Portuguese, or Spanish) and type of subjects (human). No date publication limits were 
imposed. Supplementary  1 shows the search strategy of this review. Additional data were 
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collected from randomised controlled trial (RCT) protocols. Different publications from the same 
patients’ cohort were considered as a single study for the purpose of this review. 
 
Eligibility criteria  
The following criteria were used to define study eligibility: (1) RCTs or observational studies 
comparing MitraClip procedure with mitral valve surgery and/or OMT; (2) participants with 
severe MR; and (3) information on stroke incidence after procedure. We excluded series with 
less than 20 patients or without full-text article publications. 
 
Primary and secondary outcomes 
Primary outcomes were early (<30 days) and late (>30 days) post-procedural stroke rate. 
Secondary endpoints were de novo AF and bleeding events. 
 
Data collection and management 
Two authors (PBS and JPS) systematically screened titles and abstracts of publications retrieved 
using the search strategy in order to select studies that met the inclusion criteria outlined above. 
The full text of the eligible studies was, again, independently assessed for eligibility by the two 
review team members. Any disagreement between them over the eligibility of particular studies 
was resolved through discussion and involving a third author (RT), when necessary. Data 
extraction concerned the study population, main demographics and baseline characteristics, 
interventions, and the outcomes described above. We analysed studies with multiple sequenced 
publications, ensuring no duplication of results and the collection of the most recent data.  
Some studies did not break down information on early (<30 days) vs late (>30 days) post-
procedural stroke incidence. For this reason, and to increase statistical power, we joined both 
outcomes, creating an all-stroke post-procedural rate. Post-procedural stroke incidence 
included both ischaemic and haemorrhagic cerebrovascular events, due to the lack of separate 
outcomes in the majority of studies. 
To compare bleeding events incidence, we included major bleeding and need for blood 
transfusions (>1 unit) in postoperative care. 
 
Risk of bias assessment 
Two authors (PBS, JPS) independently assessed the risk of bias of the included articles, following 
the Cochrane Collaboration's 'Risk of bias' tool for RCTs and Newcastle-Ottawa Scale for 
observational studies. RCTs were assessed as ‘low’, ‘high’ or ‘unclear’ risk for the following 
biases: random sequence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and 
other bias. None of the included studies had a blinding strategy, which resulted in a high risk for 
performance and detection bias. This assessment was expected, because the MitraClip device is 
visible on imaging studies, most studies were retrospective, and in the two RCTs on TMVR vs 
OMT there was no sham procedure. The quality assessment for each study is presented in the 
‘risk of bias summary’ (Figure 1) and Newcastle-Ottawa Scale summary (Figure 2). 
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Statistical analysis  
We pooled dichotomous non-adjusted data using odds ratios (OR) to describe effect sizes using 
the Mantel-Haenszel procedure in a random effects model. We also performed a continuity 
correction for the individual odds ratios and the overall measure, which considers adding the 
quantity 0,5 to all cells whenever relative effect measures are undefined due to the presence of 
zeros. Study heterogeneity was evaluated by funnel plots while publication bias was evaluated 
by Egger’s Test and both Galbraith and normalized Galbraith plots. To evaluate temporal trends 
on stroke incidence, a cumulative meta-analysis was performed according to date of publication, 
following a usual meta-analysis. In the cumulative analysis, studies were successively added by 
year of publication and the 95% confidence intervals (CI) and overall standardised mean 
differences were recalculated, enabling us to evaluate the outcome evolution over time. Impact 
for both age and left ventricular ejection fraction (LVEF) in stroke incidence between TMVR and 
SMVR was analyzed by meta-regression based on the mixed-effects model. 
The mean effect was considered significant if its 95% CI did not include zero. Heterogeneity was 
assessed using the I² statistic and assumed to be relevant if it exceeded 50%.  
The cumulative meta-analysis and the meta-regression was performed using R software through 
R Studio, version 1.1.463, and the traditional meta-analysis using RevMan 5.3.  
 
Results 
Search results  
Literature search identified 1447 articles, and two cited RCTs (MITRA-FR and COAPT) were 
added. After duplication removal, we excluded a total of 1194 publications based on title and 
abstract evaluation, study type (RCTs or observational studies comparing MitraClip procedure 
with SMVR and/or OMT) and study population (participants with severe MR). The full text of the 
remaining 47 studies was then screened, leading to exclusion of 35 publications: three studies 
only included outcomes of MitraClip populations, one study only reported stroke rates on the 
mitral valve surgical arm, two full texts could not be accessed, eight did not specifically refer to 
post-procedure stroke incidence, 12 were conference abstracts or RCTs’ design studies, three 
used data from the Everest trial for a different analysis and three RCTs did not yet included any 
published results; Taramasso was chosen among 4 studies based on the same institutional 
population, as it included a wider number of participants18-21. Finally, 12 publications met all the 
inclusion criteria for the qualitative review and 10 of these were suitable for the quantitative 
synthesis with meta-analysis (Figure 3). Seven studies compared TMVR versus SMVR and three 
TMVR versus OMT, providing a total of 1881 patients and 61 pooled strokes (16 in TMVR versus 
SMVR and 45 in TMVR versus OMT). Baseline characteristics of included studies are shown in 
Table 1. 
 
MitraClip versus Surgery 
We identified seven studies comparing TMVR using MitraClip with surgical repair/replacement. 
TMVR patients were older and had higher surgical risk scores than SMVR patients. Groups were 
homogeneous regarding previous AF rate (pooled OR 1.45 [0.82-2.55], Figure 4), whereas post-
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procedure de novo AF was more frequent in SMVR compared with TMVR (pooled OR 0.20 [0.06-
0.7], Figure 5), in the four studies that reported data on 30-day post-procedural AF.  
There was no significant difference in stroke incidence between TMVR and SMVR (pooled OR 
0.49 [0.17, 1.42], P=0.19, I²= 0%, Figure 6). The cumulative meta-analysis showed a significantly 
lower stroke rate in TMVR compared with SMVR (OR 0.4 [0.24, 0.67], P< 0.01, Figure 7). This 
result was evident from 2013, after adding Conradi22 to the previous studies (OR 0.46 [0.22, 
0.98], P=0.044).  
Studies were homogeneous and no selection or publication bias were identified by funnel plots, 
which was confirmed by the Galbraith or the normalized Galbraith plots (Supplementary figures 
2 to 4). Moreover, the Egger test confirmed that the normalized effects were independent from 
the precision (b = 0.38, P = 0.82, t value = 0.24; R2 = 0.013, Supplementary figure 5). Also, Begg 
and Mazumdar test confirmed that the effects were not related to their variance (kendall’s tau 
= 0.14; P = 0.77). 
Meta-regression for age and LVEF had small effect sizes with no statistically significant P-values 
(respectively Z = -0.61, p = 0.54 and Z = 0.038, P = 0.97). 
Bleeding events were less frequent in TMVR compared to SMVR (pooled OR 0.25 [0.11, 0.56], 
P<0.05, I²= 33%, Figure 8). 
 
MitraClip versus OMT 
There were five studies comparing TMVR using MitraClip plus OMT with OMT exclusively. 
However, only three of these provided data on stroke incidence during follow-up in both TMVR 
and OMT groups and were used for meta-analysis. No difference in stroke rate was identified 
(pooled OR 1.09 [0.60, 1.97], P=0.79, I²=0%, Figure 9). 
 
Discussion and Limitations 
According to our meta-analysis in the context of MR treatment: (i) the pooled stroke rate after 
TMVR, SMVR and OMT for MR patients had a low number of events; (ii) there was a trend for a 
lower stroke rate for patients submitted to TMVR compared to SMVR; (iii) there was a similar 
stroke rate for patients treated with TMVR when compared to patients allocated to OMT; and 
(iv) post-procedure AF was more frequent after SMVR when compared to TMVR patients. 
The decision to deny surgery for patients with MR is mostly based on impaired LVEF, age, and 
comorbidity1. For this reason, MitraClip patients are theoretically at increased risk for AF and 
stroke. However, our results indicate the opposite. In addition, they support the most recent 
systematic review that reported similar survival for TMVR with MitraClip and surgery, despite 
patients’ higher risk profiles in TMVR group23. However, to the best of our knowledge, this is the 
first and only meta-analysis to specifically examine stroke and de novo AF rate after mitral valve 
repair with MitraClip, comparing it with both surgery and OMT. 
 
OMT 
In patients who are not candidates for surgery, the option between TMVR with MitraClip and 
OMT alone is still debated: MITRA-FR trial17 showed that both treatments were similar regarding 
adverse effects, but the COAPT trial16 results favoured the MitraClip for the same outcome. For 
stroke incidence, our analysis showed that post-TMVR with MitraClip stroke rate was similar to 
that of patients managed with OMT alone. This finding is unexpected, as, for instance, 
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transseptal puncture for catheter ablation poses a risk for paradoxical embolism, which has 
already been described for catheter ablation of arrhythmia24. Selecting patients for 
percutaneous treatment with optimal risk–benefit balance is still subject to ongoing research. 
Hopefully, the RESHAPE-HF trial may solve the present controversy regarding MitraClip safety 
compared to conservative treatment, allowing a more sustained clinical decision25. 
 
Mitral Valve surgery 
Although regular meta-analysis suggested no significant difference in stroke incidence between 
TMVR and SMVR, a cumulative meta-analysis, added by year of publication, showed a 
significantly lower stroke rate in TMVR, compared to SMVR, suggesting a temporal trend in this 
direction26. Cumulative meta-analysis is still not a widely used statistical tool, but this 
chronological combination of studies has been proposed as a valuable method to decide when 
to stop ongoing trials or to adopt or reject an investigated treatment by different authors27, 28.  
A 2018 meta-analysis reported a negative effect of previous AF in TMVR 1-year survival rate, but 
did not address specific post-procedure adverse events or de novo AF13. However, a recent 
retrospective study comparing TMVR with MitraClip in patients with and without previous AF 
reported no significant difference in stroke incidence during follow-up 29. The lower stroke rate 
for TMVR compared with SMVR might therefore be related to its lower incidence of post-
procedure de novo AF.  
 
Antithrombotic therapy 
Only six of the 12 studies described post-procedure antithrombotic strategy, and only three 
were similar, hindering a comprehensive analysis of the used protocols. Antithrombotic therapy 
has never been formally evaluated in terms of outcome events in this setting. Both direct oral 
anticoagulants and vitamin K antagonists are currently used. However, considering 
biomechanical similarity, there is the possibility of a contraindication to direct oral 
anticoagulants in MitraClip, as in mitral stenosis and mitral prothesis9. Nevertheless, similar 
stroke incidence for TMVR and OMT indicates no concern regarding the use of direct oral 
anticoagulants after the MitraClip procedure. 
 
Future Perspectives 
The call for a specific antithrombotic strategy is justified not only by the high prevalence of AF 
in TMVR with MitraClip candidates but also by the increased risk of left atrial thrombus 
formation after the procedure, caused by acute reduction of MR and changes in hemodynamics 
within the left atrium4-7. 
Our findings suggest the need for RCTs on different post-MitraClip procedure antithrombotic 
treatments, in order to define a strict protocol, particularly for patients with AF. This is of major 
interest, because AF is highly prevalent in TMVR with MitraClip candidates and the choice of 
antithrombotic treatment has a high impact on both quality of life and health costs. 
 
Limitations 
The most important limitation of our meta-analysis is the paucity of RCTs on this issue. In fact, 
the majority of studies included were observational and not randomised, increasing the risk of 
bias and therefore limiting the strength of our results. Furthermore, for our primary outcome 
there were only 16 events among the 930 patients included in the comparison between TMVR 
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and SMVR, which is a low number of pooled events. We tried to overcome this limitation by 
applying a continuity correction and a cumulative meta-analysis28. One could argue that low 
event rate is the justification for the statistical homogeneity found (I2 = 0%), despite numerically 
heterogeneity (odds ratios range from 0.1 to 2.43), that enabled the performance of a 
cumulative meta-analysis. However, by combining study events and sample sizes, the 
cumulative meta-analysis may improve the statistical power as similar results are combined 
cumulatively. This method reduces the problem caused by the low event rate and especially by 
the presence of zero values in study groups. Regarding pooled stroke, data was not available for 
fatal versus non-fatal stroke, haemorragic stroke and transient ischemic attack. 
 
Conclusion 
Although with a low number of pooled events, our methodology showed a trend for a lower 
post-procedure stroke rate for TMVR when compared with SMVR, possibly related to a lower 
incidence of de novo AF found in the percutaneous group. For the same outcome, rates were 
similar between TMVR and OMT alone. A clinical trial comparing MitraClip patients with and 
without previous AF, with and without anticoagulant therapy in the first group, is still needed to 
resolve this dilemma. 
 
Impact on Daily Practice 
These findings may prove insightful for future recommendations regarding the conundrum of 
the best antithrombotic strategy, particularly for patients with AF. 
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Figure legends: 
Figure 1- Risk of Bias Summary 
Figure 2- Newcastle-Ottawa Scale summary 
Figure 3- Flow diagram of literature search 
Figure 4- TMVR vs. SMVR - Previous atrial fibrillation 
Figure 5- TMVR vs. SMVR - De novo atrial fibrillation 
Figure 6- TMVR vs. SMVR - All stroke incidence 
Figure 7- TMVR vs. SMVR - All stroke incidence, Cumulative Meta-analysis 
Figure 8- TMVR vs. MV Surgery – Bleeding events 
Figure 9- TMVR vs. OMT - All stroke incidence 
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Table 1- Characteristics of included studies 
Author Publication Design Control Patients no.  Mean age-years (SD) Duration of follow up 
(months) 
Post MitraClip antithrombotic 
protocol 
MitraClip Control MitraClip Control MitraClip Control 
Alozie, A 30 2017 Retrospective SMV repair or 
replacement  
42 42 82.2 (1.65) 81.7 (1.35) 9 24 3 months DAPT, followed by 
SAPT indefinitely 
Anwer, LA 31 2018 Retrospective  SMV repair 56 75 75.7 (8.6) 68.6 (13.1) 11 11 - 
Conradi, L 22 2013 Retrospective SMV repair 95 76 72.4 (8.1) 64.5 (11.4) 5 6 - 
Feldman, T 32 2011 RCT- EVEREST SMV repair or 
replacement 
184 95 67.3 (12.8) 65.7 (12.9) 60 60 Heparin during procedure, 30 
days DAPT, 6 months SAP 
Geis, N 33 2017 Retrospective OMT 86 69 68.2 (11) 53.4 (13) 24 24 Coumadin for at least 4 weeks 
post implantation 
Giannini, C 34 2016 Retrospective OMT 60 60 74 (8) 76 (8) 17 17 - 
Krawczyk-Ozog, A 35 2018 Retrospective OMT 10 23 71.8 (7.8) 73.0 (11.5) 4 4 - 
Obadia, J-F 17 2018 RCT- MITRA-FR OMT 152 152 70.1 (10.1) 70.6 (9.9) 12 12 3 months DAPT, followed by 
SAPT indefinitely 
Ondrus, T 36 2016 Retrospective Minimally invasive 
MV repair 
24 48 75 (9) 76 (4) 34 30 - 
Paranskaya, L 37 2013 Retrospective SMV repair 24 26 80 (5) 63 (12) 12 12 3 months DAPT, followed by 
SAPT indefinitely 
Stone, GW 16 2018 RCT-COAPT OMT 302 312 71.7 (11.8) 72.8 (10.5) 22.7 16.5 6 months DAPT 
Taramasso, M 18 2012 Retrospective SMV repair 52 91 68.4 (9.2) 64.9 (9.8) 8.5 18 - 
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